Clinical & Diagnostic
- With this investment, SII will acquire 20% stake in IntegriMedical -  ...
May 20, 2024 | News
Amplexd Therapeutics, Inc. (“Amplexd” or the “Company”), a clinical stage patient-scientist-led biotech company specializing in acc...
May 20, 2024 | News
Amgen announced that the U.S. Food and Drug Administration (FDA) has approved IMDELLTRA™ (tarlatamab-dlle) for the treatment of adult patients with e...
May 17, 2024 | News
A&D Company, Limited has entered into a US$1M investment agreement with Aevice Health The collaboration is geared towards jointly expand...
May 15, 2024 | News
-- The companies share design of global Phase 3 trial, iMMagine-3; will evaluate anito-cel in patients exposed to both an immunomodulatory (lMi...
May 10, 2024 | News
Taiwan-based Formosa Pharmaceuticals announced that the company has entered into an exclusive licensing agreement with Tabuk Pharmaceuticals Manufacturing ...
May 10, 2024 | News
The Global Health Innovative Technology (GHIT) Fund announced a substantial investment of approximately JPY 1.64 billion (USD 10.8 million) dedicated...
May 09, 2024 | News
Sciwind Biosciences Co., Ltd., a clinical stage biopharmaceutical company focused on developing treatments for metabolic disease, and HK inno.N Corporation...
May 07, 2024 | News
Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, announced that the U...
May 07, 2024 | News
The agreement aims to supply ImmunityBio with Bacillus Calmette-Guerin (BCG), a critical component in cancer treatment. Under the collaboration, the ...
May 06, 2024 | News
HanAll has initiated a Phase III VELOS-4 study to evaluate the efficacy and safety of tanfanercept in dry eye based on the findings from the previous Pha...
May 06, 2024 | News
Collaboration will result in BCG manufacture at large scale for use in combination with ANKTIVA®, ImmunityBio’s recently approved treatme...
May 03, 2024 | News
For organ transplant recipients, life post-transplant involves a delicate balance between invasive monitoring and immunosuppression to reduce the risk of r...
May 03, 2024 | News
Jacobio Pharma (1167.HK) announced that the data from the Phase II registrational study of the KRAS G12C inhibitor glecirasib were offically reported at th...
May 01, 2024 | News
Most Read
Bio Jobs
News
Editor Picks